Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Older Age and Increased Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms and COVID-19 Patients

Angelica D'Aiello, Sumaira Zareef, MD, Kith Pradhan, PhD, Amanda Lombardo, PA-C, BS, MS, Fariha Khatun, PA-C, Jennat Mustafa, PA-C, Alyssa De Castro, PharmD, Felisha Joseph, PA-C, Kailyn Gillick, PA-C, Anjali Naik, PA-C, Astha Thakkar, MBBS, Lauren C Shapiro, MD, Shafia Rahman, MD, Zhu Cui, MD, Jesus D Gonzalez Lugo, MD, Fiona Mienko, MBBS, Numa Tarnima Rahman, MD, Robert Lopez, MD, Heidi Chwan Ko, DO, Amanda Podolski, MD, Vikas Mehta, MD, Sanjay Goel, MD, Rafi Kabarriti, MD, Joseph Sparano, MD, Stuart Packer, MD, David Lawrence Fernandes, MD, Enrico Castelucci, MD, Margarita Kushnir, MD, Mark Chaitowitz, MD, Luca Paoluzzi, MD, Ulrich G. Steidl, MDPhD, Phaedon Zavras, MD, Ioannis Mantzaris, MD MS, Noah Kornblum, MD, Aditi Shastri, MD, Lizamarie Bachier-Rodriguez, MD, Kira Gritsman, MDPhD, Henny H. Billett, MD MSc, Rachel Bartash, MD, Yoram Puius, MD PhD, Margaret Mccort, MD, Ira Braunschweig, MD, Mendel Goldfinger, MD, Amit Verma, MBBS, R. Alejandro Sica, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-138842

Published: 2020

Journal Articles

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

Juan Carlos Ramos, MD BS, Richard F. Ambinder, MD, Joseph Sparano, MD, Jeannette Y Lee, PhD, Lawrence D Kaplan, MD, William Wachsman, MD PhD, David M. Aboulafia, MD, Ariela Noy, MD, Lee Ratner, MD PhD, David H. Henry, MD, Amy Chadburn, MD, Ethel Cesarman, MD PhD, Ronald T. Mitsuyasu, MD

Blood (2019) 134 (Supplement_1): 2872.

https://doi.org/10.1182/blood-2019-123558

Published: 2019

Journal Articles

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Juan Carlos Ramos, MD BS, Joseph Sparano, MD, Page C. Moore, PhD, Eric Siegel, Jeannette Y Lee, PhD, Erin G. Reid, MD MS, Richard F. Ambinder, MD, Amy Chadburn, MD, Paul G. Rubinstein, MD, Christine Durand, Ethel Cesarman, MD PhD, Lee Ratner, MD PhD, Robert A Baiocchi, MD PhD, David M. Aboulafia, MD, Lawrence D Kaplan, MD, Adam Capoferri, Ronald T. Mitsuyasu, MD, Ariela Noy, MD

Blood (2019) 134 (Supplement_1): 1588.

https://doi.org/10.1182/blood-2019-129687

Published: 2019

Journal Articles

Final Results of a CTEP Sponsored Phase I Study of Alistertib in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma

Stefan Klaus Barta, MD MRCP, MS, Noah Kornblum, MD, Bruce G. Raphael, MD, Kenneth B. Hymes, MD, Michael L. Grossbard, MD, Tibor Moskovits, MD, Elizabeth Handorf, Joseph Sparano, MD, Richard Piekarz, MD PhD, Catherine Diefenbach, MD

Blood (2018) 132 (Supplement 1): 4166.

https://doi.org/10.1182/blood-2018-99-116991

Published: 2018

Journal Articles

AMC-053: Pilot Study of an Oncolytic Viral Strategy Using Bortezomib with ICE +/- Rituximab for Relapsed/Refractory HIV+ Lymphomas

Erin Gourley Reid, MD, David Looney, MD, Frank Maldarelli, MD PhD, Ariela Noy, MD, David H. Henry, MD, David M. Aboulafia, MD, Juan Carlos Ramos, MD, Joseph Sparano, MD, Richard F. Ambinder, MD PhD, Jeannette Lee, PhD, Ronald T. Mitsuyasu, MD, William Wachsman, MD PhD

Blood (2016) 128 (22): 786.

https://doi.org/10.1182/blood.V128.22.786.786

Published: 2016

Journal Articles

AMC075: The Combination of Vorinostat with Chemotherapy and Rituximab Is Tolerable and Feasible in HIV-Related B-Cell Non-Hodgkin’s Lymphoma with High-Risk Features

Juan Carlos Ramos, MD, Joseph Sparano, MD, Page Moore, Jeannette Y. Lee, Michelle A Rudek, Richard F. Ambinder, Ethel Cesarman, MD PhD, Ariela Noy, MD, Ronald T. Mitsuyasu, MD

Blood (2014) 124 (21): 4473.

https://doi.org/10.1182/blood.V124.21.4473.4473

Published: 2014

Journal Articles

Long-Term Follow-up of Rituximab and Infusional Cyclophosphamide, Doxorubicin, and Etoposide (cde) in Combination with HAART in HIVRelated Non-Hodgkin’s Lymphomas (NHL).

Michele Spina, MD, Cecilia Simonelli, Emanuela Vaccher, Ulrich Jaeger, MD, Joseph Sparano, MD, Renato Talamini, Umberto Tirelli

Blood (2008) 112 (11): 1467.

https://doi.org/10.1182/blood.V112.11.1467.1467

Published: 2008

NARROW

Older Age and Increased Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms and COVID-19 Patients

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Final Results of a CTEP Sponsored Phase I Study of Alistertib in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma

AMC-053: Pilot Study of an Oncolytic Viral Strategy Using Bortezomib with ICE +/- Rituximab for Relapsed/Refractory HIV+ Lymphomas

AMC075: The Combination of Vorinostat with Chemotherapy and Rituximab Is Tolerable and Feasible in HIV-Related B-Cell Non-Hodgkin’s Lymphoma with High-Risk Features

Long-Term Follow-up of Rituximab and Infusional Cyclophosphamide, Doxorubicin, and Etoposide (cde) in Combination with HAART in HIVRelated Non-Hodgkin’s Lymphomas (NHL).

Email alerts

ASH Publications

American Society of Hematology

Older Age and Increased Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms and COVID-19 Patients

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Final Results of a CTEP Sponsored Phase I Study of Alistertib in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma

AMC-053: Pilot Study of an Oncolytic Viral Strategy Using Bortezomib with ICE +/- Rituximab for Relapsed/Refractory HIV+ Lymphomas

AMC075: The Combination of Vorinostat with Chemotherapy and Rituximab Is Tolerable and Feasible in HIV-Related B-Cell Non-Hodgkin’s Lymphoma with High-Risk Features

Long-Term Follow-up of Rituximab and Infusional Cyclophosphamide, Doxorubicin, and Etoposide (cde) in Combination with HAART in HIVRelated Non-Hodgkin’s Lymphomas (NHL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only